Merck ’s MRK stock has declined around 10.3% in the past three months, losing almost $32 billion of its market value.

Moderna's mRNA-4359 has shown early signs of efficacy, activating key proteins to trigger an immune response for cancer ...

Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other cancer stocks. In 2022, the global oncology market was valued at approximately $203.42 ...

Merck faces significant challenges, including increased competition and regulatory scrutiny for Keytruda. Keytruda is facing potential threats from competitors like Summit Therapeutics ...

In partnership with Moderna, Merck is developing a personalized mRNA therapeutic cancer vaccine (V940/mRNA-4157) to be used in combination with Keytruda. Merck & Co., Inc. (NYSE:MRK) faces a ...

A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer.

Moderna's oncology pipeline, including mRNA-4157/V940, shows promise but remains in the early stages. Despite short-term challenges, Moderna's combination vaccine could lead to long-term market ...